The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
Takashi Kojima
Honoraria - Oncolys BioPharma
Patents, Royalties, Other Intellectual Property - Astellas Amgen BioPharama (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst)
Eric Francois
No Relationships to Disclose
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical
Consulting or Advisory Role - Lilly; MSD; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Genentech (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); Eisai; MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Sung-Bae Kim
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
Se-Hoon Lee
No Relationships to Disclose
Jaafar Bennouna
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
Shen Lin
No Relationships to Disclose
Shi-Qui Qin
No Relationships to Disclose
Paula Ferreira
No Relationships to Disclose
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Sumitomo Dainippon; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Antoine Adenis
Honoraria - Bristol-Myers Squibb; SERVIER
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Sanofi; SERVIER
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Novartis; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Merck; Merck Serono; Sanofi
Peter C. Enzinger
Consulting or Advisory Role - Astellas Pharma; Five Prime Therapeutics; Merck; Taiho Pharmaceutical
Manish A. Shah
Consulting or Advisory Role - Astellas Pharma
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Merck (Inst); Oncolys BioPharma (Inst)
Ruixue Wang
No Relationships to Disclose
Pooja Bhagia
No Relationships to Disclose
S. Peter Kang
No Relationships to Disclose
Jean-Philippe Metges
No Relationships to Disclose